Sources for KLOW peptide research

The source list covers separate compounds and delivery systems. No entry reports a controlled trial of the complete KLOW blend.

KPV: uptake, inflammation and delivery

For the KLOW peptide gut argument, Dalmasso’s intestinal-cell and mouse study is the most useful starting point. Read it alongside Getting’s mechanistic work and Kannengiesser’s mouse colitis experiments; their differing designs prevent the phrase anti-inflammatory from swallowing all the detail.

The KPV hydrogel formulation study, mucoadhesive hydrogel work and targeted KPV/FK506 combination move the discussion toward delivery. The delivery literature earns its space here: it specifies how the substance reaches the tissue.

Skin, tendons and full-length protein

The 2015 GHK review gathers skin-regeneration work. The 2018 gene-data review pursues a different question, and the 2025 mouse colitis paper moves GHK-Cu into an experimental gut-disease setting.

For repair claims, the main landmarks are the rat Achilles tendon study of BPC-157 and the rat wound study of full-length thymosin beta-4. The two-person BPC-157 intravenous pilot and 2026 musculoskeletal review belong beside them when judging how far the human evidence has progressed.

The skin-adaptive film dressing paper concerns growth-factor release in a rodent diabetic-wound model. It is neighbouring biomaterials research, rather than a direct test of KPV or KLOW. Its place in the source list does not change the substance it studied.

Source register

Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. ↗
Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. ↗
Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. ↗
Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. ↗
Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20-24. ↗
Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. ↗
Getting SJ, Christian HC, Lam CW, et al. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. 2003;306(2):631-637. ↗
Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. ↗
Zhou F, et al. In situ mucoadhesive hydrogel capturing tripeptide KPV: the anti-inflammatory, antibacterial and repairing effect. Biomater Sci. 2022;10(7):1644-1655. ↗
Zhang Q, et al. Self-Cross-Linked Hydrogel of Cysteamine-Grafted gamma-Polyglutamic Acid Stabilized Tripeptide KPV for Treating Inflammatory Bowel Disease. ACS Biomater Sci Eng. 2021;7(10):4938-4949. ↗
Zhao Y, et al. Skin-adaptive film dressing with smart-release of growth factors accelerated diabetic wound healing. Int J Biol Macromol. 2022;222(Pt A):1738-1748. ↗
Sun Q, et al. PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combination treatment of acute and chronic DSS-induced colitis. Front Pharmacol. 2024. ↗
Mao S, Huang J, Li J, Sun F, Zhang Q, Cheng Q, Zeng W, Lei D, Wang S, Yao J. Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms. Frontiers in Pharmacology. 2025. ↗